Skip to content

Edaravone

    Brands

    DEA Class;  Rx

    Common Brand Names; Radicava, Radicava ORS

    • Neurologics, Other

    Oral and intravenous antioxidant
    Used for treatment of amyotrophic lateral sclerosis (ALS)
    Hypersensitivity reactions, including anaphylaxis, reported

    Indicated for amyotrophic lateral sclerosis (ALS)

    Hypersensitivity to drug or any of its excipients

    • Contusion (15%)
    • Gait disturbance (13%)
    • Headache (10%)
    • Dermatitis (8%)
    • Eczema (7%)
    • Respiratory failure, respiratory disorder, hypoxia (6%)
    • Glycosuria (4%)
    • Tinea infection (4%)
    • Skin and subcutaneous tissue disorders: Hypersensitivity reactions and anaphylaxis

    Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) reported; monitor for hypersensitivity reactions; if hypersensitivity reactions occur, discontinue drug, treat per standard of care, and monitor until condition resolves

    Contains sodium bisulfite, which may cause allergic type-reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people; sulfite sensitivity occurs more often with history of asthma

    There are no adequate data on the developmental risk associated with use in pregnant women

    Unknown if distributed in human breast milk

    Excreted in the milk of lactating rats

    Adults

    105 mg/dose PO; 60 mg/dose IV.

    Geriatric

    105 mg/dose PO; 60 mg/dose IV.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Edaravone

    solution for IV infusion (Radicava)

    • 30mg/100mL single-dose polypropylene bag

    oral suspension (Radicava ORS)

    • 105mg/5mL